Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.
Frequently asked questions
What sector does Wuhan Thalys Med Tech Co Ltd (603716) operate in?
Wuhan Thalys Med Tech Co Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Wuhan Thalys Med Tech Co Ltd (603716) current stock price?
As of the latest data, Wuhan Thalys Med Tech Co Ltd stock price is CN¥15.87, with a previous close of CN¥16.01. Wuhan Thalys Med Tech Co Ltd lost -CN¥0.14 in the last trading session, representing a -0.87% loss.
What is Wuhan Thalys Med Tech Co Ltd (603716) current market capitalization?
Wuhan Thalys Med Tech Co Ltd market cap is approximately 3.58 billion.
What is Wuhan Thalys Med Tech Co Ltd (603716) Earnings Per Share (EPS)?
The trailing EPS is -CN¥0.97.
Does Wuhan Thalys Med Tech Co Ltd (603716) pay dividends?
No. Wuhan Thalys Med Tech Co Ltd does not pay a dividend.
What is Wuhan Thalys Med Tech Co Ltd (603716) beta (volatility) score?
Wuhan Thalys Med Tech Co Ltd has a beta of 0.688, indicating lower volatility than the overall market.
